help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Journal of Clinical Endocrinology & Metabolism Vol. 25, No. 6 784-791
doi:10.1210/jcem-25-6-784
Copyright © 1965 by the Endocrine Society.
This Article
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints, Permissions and Rights
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by ADADEVOH, B. K.
Right arrow Articles by GRAY, C. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by ADADEVOH, B. K.
Right arrow Articles by GRAY, C. H.

Metabolism of Progesterone-4-14C by Adrenal Tissue from a Patient with Cushing's Syndrome1,,2

B. K. ADADEVOH3, LEWIS L. ENGEL4, D. SHAW and C. H. GRAY

The John Collins Warren Laboratories of the Huntington Memorial Hospital of Harvard University at the Massachusetts General Hospital and the Department of Biological Chemistry, Harvard Medical School Boston, Massachusetts
Department of Chemical Pathology, King's College Hospital Medical School Denmark Hill, London, S.E.5, England

Minced adrenal tissue from a woman with Cushing's syndrome was incubated with progesterone-4-14C. After addition of carrier steroids and their reisolation by gradient elution partition chromatography and paper chromatography, radiochemical purity was established by repeated crystallization, derivative formation and countercurrent distribution. The following metabolic products were identified: {Delta}4-androstene-3,17-dione (2.3%),11β-hydroxy-{Delta}4-androstene-3,17-dione (0.3%), 17,21-dihydroxy-{Delta}4-pregnene-3,20-dione (1.2%), cortisol (2.5%), deoxycorticosterone (6.2%), 16{alpha}hydroxy-{Delta}4-pregnene-3,20-dione (24.8%), 2 unidentified compounds (18.1%) and unreacted progesterone (9.1%).

1 This is publication No. 1202 of the Cancer Commission of Harvard University. This work was supported by Grants CA 01393 and CA 02421 from the National Cancer Institute, USPHS, and Grant P95 from the American Cancer Society, Inc. A preliminary account of this work was presented at the Sixth International Congress of Biochemistry, New York, July, 1964. Congress Abstracts VII-1.

2 The authors thank Professors A. Haddow, E. Boyland and D. W. Smithers for making available to one of us (L. L. E.) laboratory facilities in the Chester Beatty Research Institute and the Radiobiology Department of the Royal Marsden Hospital.

3 Rockefeller Foundation Fellow, 1962–64.

Present address: University of Lagos Medical School, Lagos, Nigeria.

4 Permanent Faculty Fellow of the American Cancer Society.

Received January 6, 1965.

Accepted February 4, 1965.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1965 by The Endocrine Society